

## Special Issue

# Epigenetic Regulation for Cancer Chemoprevention

### Message from the Guest Editor

Epigenetic modulation for cancer therapy is an emerging and promising approach in the field of oncology. Heritable changes in gene expression that occur without any changes to the DNA sequence are called epigenetics. In cancer, genes that promote tumor growth, invasion, and metastasis may be expressed aberrantly due to epigenetic modifications. Cancer therapy has become more attractive by targeting epigenetic changes. The aim of this Special Issue is to provide a platform on which to share cutting-edge discoveries, novel strategies, and therapeutic approaches that target epigenetic modifications in cancer. Submissions can cover a range of topics, including, but not limited to, the following:

- DNA methylation inhibitors used for the treatment of cancer.
- Histone-modification-targeted therapies to treat various cancer types.
- Non-coding RNAs as epigenetic regulators in cancer.
- Epigenetic biomarkers in the diagnosis and prognosis of cancer.
- Epigenetic-based combination therapies.
- Mechanisms involved in epigenetic dysregulation in diverse cancer subtypes.
- Potential of epigenetic editing for precision cancer medicine.

---

### Guest Editor

Dr. Zheng-Yuan Su

Department of Bioscience Technology, Chung Yuan Christian University, Taoyuan City 320314, Taiwan

---

### Deadline for manuscript submissions

closed (31 October 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/188487](https://mdpi.com/si/188487)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).